Synapse - Works

Results (13087)

Splicing modulators impair DNA damage response and induce killing of cohesin-mutant MDS/AML

Meeting Abstract

Wheeler, E. C.; Martin, B.; Doyle, W.; Gorelov, R.; Donahue, M.; Jann, J. C.; Abdel-Wahab, O.; Taylor, J.; Seiler, M.; Buonamici, S.; more...
Blood (2022)

Fulltext@MSK | Save

Molecular Response of ≤10% BCR::ABL1(IS) is predictive of positive outcomes in treatment-resistant patients with chronic phase chronic myeloid leukemia (CP-CML) treated with ponatinib from the phase 2 optic trial

Meeting Abstract

Apperley, J. F.; Cortes, J. E.; Jabbour, E.; Hochhaus, A.; Hughes, T.; Chuah, C.; de Lavallade, H.; Deininger, M. W.; Lipton, J. H.; Lomaia, E.; more...
Blood (2022)

Fulltext@MSK | Save

Treatment free remission after combination therapy with asciminib (ABL001) plus imatinib in chronic phase chronic myeloid leukemia (CP-CML) patients who relapsed after a prior attempt at TKI discontinuation-H Jean Khoury Cure CML Consortium study

Meeting Abstract

Mauro, M.; Visotcky, A.; Flynn, K. E.; Radich, J. P.; Yang, J.; Oehler, V. G.; Cortes, J. E.; Kota, V. K.; Tantravahi, S. K.; Baim, A.; more...
Blood (2022)

Fulltext@MSK | Save

ASC2ESCALATE: A phase 2, single-arm, dose-escalation study of asciminib monotherapy in patients (Pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with 1 prior tyrosine kinase inhibitor (TKI)

Meeting Abstract

Sasaki, K.; Mauro, M.; Levy, M. Y.; Atallah, E. L.; Koller, P. B.; Maegawa, R.; Damon, A.; Kumar, J.; Khan, M.; Cortes, J. E.
Blood (2022)

Fulltext@MSK | Save

First-in-human study of Elvn-001, a highly selective BCR::ABL1 tyrosine kinase inhibitor, in patients with chronic myeloid leukemia who failed previous tyrosine kinase inhibitor therapies

Meeting Abstract

Hughes, T.; Mauro, M.; Branford, S.; Deng, W.; Wang, Q.; Collins, H.; Hochhaus, A.
Blood (2022)

Fulltext@MSK | Save

Phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/ essential thrombocythemia myelofibrosis

Meeting Abstract

Bewersdorf, J. P.; Verstovsek, S.; Derkach, A.; Masarova, L.; Pemmaraju, N.; Stein, E.; Mauro, M.; Rampal, R. K.; Bose, P.
Blood (2022)

Fulltext@MSK | Save

Dynamics of response and response factors in patients (Pts) with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs) in the phase 3 Ascembl study

Meeting Abstract

Hughes, T.; Rea, D.; Boquimpani, C.; Minami, Y.; Mauro, M.; Cortes, J. E.; Apperley, J. F.; García Gutiérrez, V.; Kapoor, S.; Allepuz, A.; more...
Blood (2022)

Fulltext@MSK | Save

Epidemiological impact of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin and prednisone (Pola-R-CHP) use in previously untreated diffuse large B-cell lymphoma (DLBCL) in terms of second line (2L) treatment: An ad hoc analysis from the POLARIX study

Meeting Abstract

Boissard, F.; Tilly, H.; Lenz, G.; Collins, G. P.; Pinto, A.; Sehn, L. H.; Salles, G.; Roussel, M.; Simonella, L.; Ho, R.; more...
Blood (2022)

Fulltext@MSK | Save

Radiotherapy for secondary CNS lymphoma: Patterns of utilization and clinical outcomes

Meeting Abstract

Cederquist, G. Y.; Tringale, K. R.; Hajj, C.; Hubbeling, H.; Fregonese, B.; Lee, J.; Scordo, M.; Grommes, C.; Yahalom, J.; Imber, B. S.
Blood (2022)

Fulltext@MSK | Save

The second generation type II JAK2 inhibitor, AJ1-10502, demonstrates enhanced selectivity, improved therapeutic efficacy and reduced mutant cell fraction compared to type I JAK2 inhibitors in models of myeloproliferative neoplasms (MPNs)

Meeting Abstract

Rai, S.; Stetka, J.; Usart, M.; Hao-Shen, H.; Park, Y.; Houston, R.; Martinez Benitez, A. R.; Wereski, M.; Guzzardi, E.; Persaud, S.; more...
Blood (2022)

Fulltext@MSK | Save